📊 NSRX Key Takeaways
Is Nasus Pharma Ltd (NSRX) a Good Investment?
Nasus Pharma Ltd lacks sufficient financial data for meaningful fundamental analysis, with nearly all income statement, balance sheet, and cash flow metrics unavailable. The single Form 4 filing in the last 90 days provides minimal insight into operational health or management confidence.
Insufficient SEC financial data prevents evaluating profitability, liquidity, or growth quality for Nasus Pharma Ltd. A neutral stance is prudent until audited statements clarify revenue traction, cash position, and R&D spending efficiency.
Nasus Pharma Ltd Key Strengths (NSRX)
- Recent insider activity suggests ongoing management engagement
- Pharma sector participation provides exposure to healthcare industry
- Listed on NYSE indicates regulatory compliance and public market access
- Exposure to large therapeutic markets typical of pharmaceutical preparations
- Potential high-margin profile if products gain approval and commercial traction
- Operational leverage potential as fixed R&D spreads over sales
NSRX Stock Risks: Nasus Pharma Ltd Investment Risks
- Complete absence of revenue and profitability data prevents financial health assessment
- No balance sheet metrics available to evaluate solvency or liquidity position
- Unknown cash flow status raises concerns about operational viability and burn rate
- Insufficient data freshness suggests potential reporting delays or financial distress
- Lack of disclosed metrics (only 1 available) indicates material information gaps
- Lack of current financial disclosure limits assessment of profitability and solvency
- Possible pre-revenue status with uncertain path to commercialization
- Cash runway uncertainty and dilution risk if external financing is needed
Key Metrics to Watch
- Revenue generation and year-over-year growth trends
- Net cash position and monthly cash burn rate
- Clinical trial progress and regulatory milestone achievements
- Current ratio and days cash on hand for liquidity assessment
- Cash and equivalents with quarterly operating cash burn/runway
- Revenue initiation and gross margin once commercialization begins
Nasus Pharma Ltd (NSRX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
NSRX Profit Margin, ROE & Profitability Analysis
NSRX vs Healthcare Sector: How Nasus Pharma Ltd Compares
How Nasus Pharma Ltd compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Nasus Pharma Ltd Stock Overvalued? NSRX Valuation Analysis 2026
Based on fundamental analysis, Nasus Pharma Ltd has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Nasus Pharma Ltd Balance Sheet: NSRX Debt, Cash & Liquidity
NSRX Revenue Growth, EPS Growth & YoY Performance
NSRX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Nasus Pharma Ltd (CIK: 0002029039)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NSRX
What is the AI rating for NSRX?
Nasus Pharma Ltd (NSRX) has a Combined AI Grade of B from Claude (B) and ChatGPT (B) with 18% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NSRX's key strengths?
Claude: Recent insider activity suggests ongoing management engagement. Pharma sector participation provides exposure to healthcare industry. ChatGPT: Exposure to large therapeutic markets typical of pharmaceutical preparations. Potential high-margin profile if products gain approval and commercial traction.
What are the risks of investing in NSRX?
Claude: Complete absence of revenue and profitability data prevents financial health assessment. No balance sheet metrics available to evaluate solvency or liquidity position. ChatGPT: Lack of current financial disclosure limits assessment of profitability and solvency. Possible pre-revenue status with uncertain path to commercialization.
What is NSRX's revenue and growth?
Nasus Pharma Ltd reported revenue of N/A.
Does NSRX pay dividends?
Nasus Pharma Ltd does not currently pay dividends.
Where can I find NSRX SEC filings?
Official SEC filings for Nasus Pharma Ltd (CIK: 0002029039) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NSRX's EPS?
Nasus Pharma Ltd has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is NSRX's fundamental grade?
Based on our AI fundamental analysis in June 2026, Nasus Pharma Ltd has a B grade with 18% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is NSRX stock overvalued or undervalued?
Valuation metrics for NSRX: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is NSRX's AI grade for 2026?
Our dual AI analysis gives Nasus Pharma Ltd a combined B grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NSRX's free cash flow?
Nasus Pharma Ltd's operating cash flow is N/A, with capital expenditures of N/A.
How does NSRX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).